Jeffrey Blumenstein

Jeffrey Blumenstein has extensive work experience in the pharmaceutical industry, with a focus on regulatory Chemistry, Manufacturing, and Control (CMC) and quality assurance. Jeffrey is currently serving as the VP-CMC at Aditum Bio starting from November 2021. Before that, they worked at Jazz Pharmaceuticals from June 2018 to November 2021 as the Executive Director, New Product and Technical Integration.

Prior to Jazz Pharmaceuticals, Jeffrey held various roles at Johnson & Johnson from 2007 to 2018, including Strategy & Operations Support Leader-CV & Metabolism and VP-CMC Teams.

Jeffrey also worked at Pfizer for almost a decade, starting in 1998, where they served as the Global Head Reg CMC & QA. In this position, Jeffrey led globally distributed teams and was responsible for the Chemistry, Manufacturing, and Control (CMC) sections of regulatory submissions and GMP quality in development and manufacturing operations.

Before joining Pfizer, Jeffrey worked at The Janssen Pharmaceutical Companies of Johnson & Johnson as the Group Director Reg CMC from 1994 to 1998. In this role, they were responsible for the CMC sections of regulatory submissions and provided technical support to project teams.

Jeffrey's career began at the FDA, where they worked as a Supervisory Chemist-Oncology from 1990 to 1994. Jeffrey held the same role at the FOOD AND DRUG ADMINISTRATION CDER during the same period.

Overall, Jeffrey Blumenstein has a strong background in regulatory CMC and quality assurance leadership positions across multiple pharmaceutical companies.

Jeffrey Blumenstein attended the Massachusetts Institute of Technology from 1982 to 1987. During this time, they pursued their Doctor of Philosophy (Ph.D.) in Organic Chemistry and successfully completed the program.